IMM Stock Overview
A biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ImmuPharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.012 |
| 52 Week High | UK£0.03 |
| 52 Week Low | UK£0.0082 |
| Beta | 1.59 |
| 1 Month Change | 0.21% |
| 3 Month Change | -34.61% |
| 1 Year Change | -25.63% |
| 3 Year Change | -83.18% |
| 5 Year Change | -92.62% |
| Change since IPO | -97.70% |
Recent News & Updates
Shareholder Returns
| IMM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -1.8% | 0.3% | 0.4% |
| 1Y | -25.6% | -4.7% | 3.9% |
Return vs Industry: IMM underperformed the UK Pharmaceuticals industry which returned -4.7% over the past year.
Return vs Market: IMM underperformed the UK Market which returned 3.9% over the past year.
Price Volatility
| IMM volatility | |
|---|---|
| IMM Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: IMM's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: IMM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 5 | Tim McCarthy | www.immupharma.co.uk |
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company’s lead product candidate is the P140 (Lupuzor), a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140 which is in Phase II for chronic inflammatory demyelinating polyneuropathy, a progressive inflammatory condition of the nerves; and P140 in other indications for asthma, gout, periodontitis, and IBD.
ImmuPharma plc Fundamentals Summary
| IMM fundamental statistics | |
|---|---|
| Market cap | UK£5.02m |
| Earnings (TTM) | -UK£2.46m |
| Revenue (TTM) | n/a |
-72.5x
P/S Ratio-2.1x
P/E RatioIs IMM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMM income statement (TTM) | |
|---|---|
| Revenue | -UK£69.96k |
| Cost of Revenue | UK£0 |
| Gross Profit | -UK£69.96k |
| Other Expenses | UK£2.39m |
| Earnings | -UK£2.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0059 |
| Gross Margin | 100.00% |
| Net Profit Margin | 3,519.61% |
| Debt/Equity Ratio | 0% |
How did IMM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 20:25 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ImmuPharma plc is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Pye | Cavendish |
| null null | Cavendish |
| Navid Malik | Cavendish Historical (Cenkos Securities) |